- $18.69m
- -$43.47m
- $1.68m
- 28
- 33
- 19
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.65% | ||
| Return on Equity | -70.32% | ||
| Operating Margin | -3842.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3.94 | 0.54 | 0.32 | 1.68 | 3.65 | 5.61 | -24.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 19th, 2022
- Public Since
- June 30th, 2021
- No. of Shareholders
- 38
- No. of Employees
- 68
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 78,509,823
- Address
- 71 Commercial Street, Mailbox 312, BOSTON, 02109
- Web
- https://www.akiliinteractive.com/
- Phone
- +1 6174560597
- Auditors
- KPMG LLP
Upcoming Events for AKLI
Q1 2024 Akili Inc Earnings Release
Q2 2024 Akili Inc Earnings Release
Similar to AKLI
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Akili share price?
As of Today at 19:01 UTC, shares in Akili are trading at $0.24. This share price information is delayed by 15 minutes.
How has the Akili share price performed this year?
Shares in Akili last closed at $0.24 and the price had moved by -80.96% over the past 365 days. In terms of relative price strength the Akili share price has underperformed the S&P500 Index by -84.16% over the past year.
What are the analyst and broker recommendations for Akili?
The overall consensus recommendation for Akili is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Akili dividend yield?
Akili does not currently pay a dividend.
Does Akili pay a dividend?
Akili does not currently pay a dividend.
When does Akili next pay dividends?
Akili does not currently pay a dividend.
How do I buy Akili shares?
To buy shares in Akili you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akili?
As of the previous close price of $0.24, shares in Akili had a market capitalisation of $18.69m.
Where are Akili shares listed?
Here are the trading details for Akili:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AKLI
What kind of share is Akili?
Based on an overall assessment of its quality, value and momentum Akili is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akili share price forecast for 2024?
The analyst consensus target price for shares in Akili is $0.65. That is 173.11% above the last closing price of $0.24.
Analysts covering Akili currently have a consensus Earnings Per Share (EPS) forecast of -$0.51 for the next financial year.
What is the trend in the Akili share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akili. Over the past six months, its share price has underperformed the S&P500 Index by -56.83%.
As of the last closing price of $0.24, shares in Akili were trading -57.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akili PE Ratio?
The Akili PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akili?
We do not have data on Akili's directors